The following is a list of the 15 authors' ICMJE conflict of interest disclosures that were submitted to the journal, Pediatrics, but were not published in the 2013 acne treatment guidelines. These disclosures include money that the authors received for thier work, in addition to the money that was granted to their institutions for their work. Additionally, I have included the approximate total amounts of money that these authors have disclosed receiving from industry based on ProPublica information in [bolded font]. I have added the sums of money disclosed for each author. Where ranges of payment amounts are provided, the lowest amount is used in my calculations (i.e. for "$100-500," the value used would be $100). For further information on these amounts, please visit http://www.propublica.org/series/dollars-for-docs and "search" the names of the doctors of your choice:
- Lawrence F. Eichenfield, MD: American Acne and Rosacea Society, Galderma, Medicis-Valeant, Steifel-GSK, Bayer, Physician Resources (Galderma-associated), Medicis-Valeant, Johnson & Johnson, Neutrogena [US$88,033]
- Andrew C. Krakowski, MD: American Acne and Rosacea Society [US$0-100]
- Caroline Piggott, MD: American Acne and Rosacea Society, Galderma [none disclosed]
- James Del Rosso, DO: American Acne and Rosacea Society, Allergan, Bayer, Galderma, Medicis, Promius, Ranbaxy, Warner-Chilcott, Valeant, Tria, Dermira [US$85,141]
- Hilary Baldwin, MD: Galderma, Valeant, Ranbaxy, Allergan [US$204,755]
- Sheila Fallon Friedlander, MD: American Acne and Rosacea Society, Galderma [US$3,500]
- Moise Levy, MD: American Acne and Rosacea Society, Galderma, Valeant, TopMD, Stiefel/GSK, Johnson & Johnson, Pierre-Fabre [US$12,524]
- Anne Lucky, MD: Galderma [none disclosed]
- Anthony J. Mancini, MD: American Acne and Rosacea Society, American Academy of Pediatrics, Galderma, Coria/Valeant, Medicis, Spire Learning, Global Prairie, Physician Resources, Inc., Elsevier [US$5,940]
- Seth J. Orlow, MD, PhD: American Acne and Rosacea Society, Dermira, Galderma, Hoffman La-Roche [US$14,000]
- Albert C. Yan, MD: American Acne and Rosacea Society, Galderma [US$2,000]
- Keith K. Vaux, MD: American Acne and Rosacea Society [none disclosed]
- Guy Webster, MD, PhD: Galderma, Valeant, Medicis, Ranbaxy, Cipher, Tolmar [US$9,241]
- Andrea L. Zaenglein, MD: American Acne and Rosacea Society, Galderma, Promius, Johnson & Johnson, Valeant, TopMD, Astellas, Textbook royalties: Pediatric Dermatology [US$7,292]
- Diane M. Thiboutot, MD: American Acne and Rosacea Society, Allergan, Galderma, Photocure, Steifel/GSK, Valeant [US$28,394]
Furthermore, the American Acne & Rosacea Society received 98% of its income in 2012 from drug companies and paid the Academy of Pediatrics "an undisclosed sum" of money for the publication of this 2013 acne treatment guideline.
Professor of pediatrics at Johns Hopkins School of Medicine and former editor of the Journal of the American Medical Association (JAMA), Catherine DeAngeles, says that she is suspicious of these guidelines because "[t]he basis for these guidelines seems to be marketing, not science."
Investigative journalism revealed that, in 2011, Galderma Laboratories gave the American Acne and Rosacea Society its largest contribution in 2011 at US$176,000, making it a "Diamond Benefactor." Authors on the 2013 guideline in question also worked as consultants and speakers for Galderma Laboratories.
Diamond Benefactors are sponsors who donate at least US$75,000 to the American Acne and Rosacea Society. In addition to Galderma, other Diamond Benefactors include the following drug companies:
- Promius Pharma,
- Stiefel GSK,
- Valeant Pharmaceuticals Int. Inc.,
- Bayer, and
Undisclosed Conflicts: A Blemish On Acne Treatment Guidelines?
2013 Acne Treatment Guideline in question: Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne
Authors' COI disclosures: http://freepdfhosting.com/1f1191fe4e.pdf